Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Monday, January 12, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences has outlined its strategic priorities for 2026, focusing on advancing its clinical-stage programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The ongoing Phase 1/2a ELIMINATE-B trial for PBGENE-HBV is set to provide data updates at medical conferences in 2026. Additionally, the company anticipates IND clearance for PBGENE-DMD in Q1 2026, with initial patient data expected later that year.
Price reaction · baseline $3.92 (2026-01-09 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
Ongoing Phase 1/2a trial for PBGENE-HBV shows commitment to research.
Expected IND clearance for PBGENE-DMD indicates progress in development.
Data updates anticipated at medical conferences in 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026 Unaudited cash, cash
Frequently Asked Questions
What are the strategic priorities for Precision BioSciences in 2026?
Precision BioSciences aims to advance its clinical-stage programs PBGENE-HBV and PBGENE-DMD.
When will data updates for PBGENE-HBV be available?
Data updates for the PBGENE-HBV trial are expected at medical conferences in 2026.
What is the status of the PBGENE-DMD program?
PBGENE-DMD is expecting IND clearance in Q1 2026 for its Phase 1/2 FUNCTION-DMD study.
When can we expect initial data for PBGENE-DMD?
Initial data from multiple patients in the PBGENE-DMD study is expected in 2026.